TapewireFind a company

person · Reporting owner

ENRIGHT PATRICK G

Disclosed activity across 22 companies

Tapewire entity
847
SEC CIK
0001253886

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Aptinyx Inc.APTX · Entity 120922DirectorMay 26, 2022May 31, 2022
Axonics, Inc.AXNX · Entity 8600410% ownerNovember 02, 2018November 02, 2018
BioAge Labs, Inc.BIOA · Entity 5569DirectorJune 10, 2026June 12, 2026
CORCEPT THERAPEUTICS INCCORT · Entity 2620DirectorMarch 16, 2017March 20, 2017
Inozyme Pharma, Inc.INZY · Entity 7771710% ownerApril 19, 2022April 21, 2022
Jazz Pharmaceuticals plcJAZZ · Entity 818DirectorAugust 31, 2026September 02, 2026
Lexeo Therapeutics, Inc.LXEO · Entity 568710% ownerNovember 07, 2023November 10, 2023
Molecular Templates, Inc.MTEM · Entity 8598710% ownerAugust 28, 2020September 01, 2020
Tourmaline Bio, Inc.TALS · Entity 1564310% ownerMay 11, 2021May 11, 2021
Vaxcyte, Inc.PCVX · Entity 116410% ownerJune 11, 2020June 11, 2020
Venus Concept Inc.VERO · Entity 5530410% ownerNovember 07, 2019November 08, 2019
Vera Therapeutics, Inc.VERA · Entity 4358DirectorMay 21, 2026May 26, 2026
Veradermics, IncMANE · Entity 1907Director · 10% ownerFebruary 03, 2026February 06, 2026
Zenas BioPharma, Inc.ZBIO · Entity 275DirectorJune 15, 2026June 17, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aptinyx Inc.

Report date May 26, 2022 · Filed May 31, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2032-05-25Direct40,000 Reported balance After 2022-05-26 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2022-05-26 · Grant · Acquired 40,000 · Balance 40,000

F1: This option vests in ratable monthly installments over one year from the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: This option vests in ratable monthly installments over one year from the date of grant.

Axonics, Inc.

Report date November 02, 2018 · Filed November 02, 2018

Jointly reported with Longitude Capital Partners III, LLC, Longitude Venture Partners III, L.P.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Longitude Venture Partners III, L.P.2,933,333 Last balance in matching sequence After 2018-11-02 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 1 · 2018-11-02 · Conversion · Acquired 2,400,000 · Balance 2,400,000

F1: Reflects a 1.2-for-1 forward stock split of the Issuer's common stock effected on October 18, 2018.

F2: Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series C preferred stock automatically converted into 1.2 shares of the Issuer's common stock. The Series C preferred stock had no expiration date.

F3: These shares are held directly by Longitude Venture Partners III, L.P. ("Longitude Venture III"). Longitude Capital Partners III, LLC ("Longitude Capital III") is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker, a member of the Issuer's board of directors, are the managing members of Longitude Capital III (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of Longitude Capital III and the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Row 2 · 2018-11-02 · Purchase · Acquired 533,333 · Balance 2,933,333

F1: Reflects a 1.2-for-1 forward stock split of the Issuer's common stock effected on October 18, 2018.

F3: These shares are held directly by Longitude Venture Partners III, L.P. ("Longitude Venture III"). Longitude Capital Partners III, LLC ("Longitude Capital III") is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker, a member of the Issuer's board of directors, are the managing members of Longitude Capital III (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of Longitude Capital III and the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Series C Preferred StockSEC Table II · derivative / convertible securityIndirectBy Longitude Venture Partners III, L.P.0 Reported balance After 2018-11-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2018-11-02 · Conversion · Disposed 2,000,000 · Balance 0

F2: Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series C preferred stock automatically converted into 1.2 shares of the Issuer's common stock. The Series C preferred stock had no expiration date.

F1: Reflects a 1.2-for-1 forward stock split of the Issuer's common stock effected on October 18, 2018.

F3: These shares are held directly by Longitude Venture Partners III, L.P. ("Longitude Venture III"). Longitude Capital Partners III, LLC ("Longitude Capital III") is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker, a member of the Issuer's board of directors, are the managing members of Longitude Capital III (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of Longitude Capital III and the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects a 1.2-for-1 forward stock split of the Issuer's common stock effected on October 18, 2018.

F2: Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series C preferred stock automatically converted into 1.2 shares of the Issuer's common stock. The Series C preferred stock had no expiration date.

F3: These shares are held directly by Longitude Venture Partners III, L.P. ("Longitude Venture III"). Longitude Capital Partners III, LLC ("Longitude Capital III") is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker, a member of the Issuer's board of directors, are the managing members of Longitude Capital III (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of Longitude Capital III and the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

BioAge Labs, Inc.

Report date June 10, 2026 · Filed June 12, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.48 · Expires 2036-06-09Direct22,000 Reported balance After 2026-06-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-06-10 · Grant · Acquired 22,000 · Balance 22,000

F1: The entire option award shall vest on the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The entire option award shall vest on the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date.

CORCEPT THERAPEUTICS INC

Report date March 16, 2017 · Filed March 20, 2017

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy LVP5,721,372 Reported balance After 2017-03-16 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 1 · 2017-03-16 · Sale · Disposed 264,650 · Balance 5,721,372

F1: Reflects sales of common stock of the Issuer executed in multiple transactions at prices ranging from $9.855 to $10.255 per share. The price reported reflects the weighted-average price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F2: Reflects the pro rata distribution by Longitude Venture Partners, L.P. ("LVP") and Longitude Capital Partners, L.P. ("LCA") on March 16, 2017 of shares of common stock of the Issuer to their respective partners for no consideration, and the subsequent pro rata distribution by Longitude Capital Partners, LLC ("LCP"), the sole general partner of LVP and LCA, on March 16, 2017 of shares of common stock of the Issuer to its members for no consideration. As a result of these distributions, the Reporting Person received and became the direct holder of 68,071 shares of common stock of the Issuer.

F3: Reflects shares of common stock of the Issuer held of record by LVP and LCA. Mr. Enright is a managing member of LCP, the sole general partner of LVP and LCA. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by LVP and LCA, except to the extent of his pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy LCA114,675 Reported balance After 2017-03-16 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 2 · 2017-03-16 · Sale · Disposed 5,305 · Balance 114,675

F1: Reflects sales of common stock of the Issuer executed in multiple transactions at prices ranging from $9.855 to $10.255 per share. The price reported reflects the weighted-average price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F2: Reflects the pro rata distribution by Longitude Venture Partners, L.P. ("LVP") and Longitude Capital Partners, L.P. ("LCA") on March 16, 2017 of shares of common stock of the Issuer to their respective partners for no consideration, and the subsequent pro rata distribution by Longitude Capital Partners, LLC ("LCP"), the sole general partner of LVP and LCA, on March 16, 2017 of shares of common stock of the Issuer to its members for no consideration. As a result of these distributions, the Reporting Person received and became the direct holder of 68,071 shares of common stock of the Issuer.

F3: Reflects shares of common stock of the Issuer held of record by LVP and LCA. Mr. Enright is a managing member of LCP, the sole general partner of LVP and LCA. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by LVP and LCA, except to the extent of his pecuniary interest therein.

Common StockSEC Table I · non-derivativeDirect272,281 Reported balance Holding disclosure · report date 2017-03-16 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 272,281

F2: Reflects the pro rata distribution by Longitude Venture Partners, L.P. ("LVP") and Longitude Capital Partners, L.P. ("LCA") on March 16, 2017 of shares of common stock of the Issuer to their respective partners for no consideration, and the subsequent pro rata distribution by Longitude Capital Partners, LLC ("LCP"), the sole general partner of LVP and LCA, on March 16, 2017 of shares of common stock of the Issuer to its members for no consideration. As a result of these distributions, the Reporting Person received and became the direct holder of 68,071 shares of common stock of the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects sales of common stock of the Issuer executed in multiple transactions at prices ranging from $9.855 to $10.255 per share. The price reported reflects the weighted-average price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F2: Reflects the pro rata distribution by Longitude Venture Partners, L.P. ("LVP") and Longitude Capital Partners, L.P. ("LCA") on March 16, 2017 of shares of common stock of the Issuer to their respective partners for no consideration, and the subsequent pro rata distribution by Longitude Capital Partners, LLC ("LCP"), the sole general partner of LVP and LCA, on March 16, 2017 of shares of common stock of the Issuer to its members for no consideration. As a result of these distributions, the Reporting Person received and became the direct holder of 68,071 shares of common stock of the Issuer.

F3: Reflects shares of common stock of the Issuer held of record by LVP and LCA. Mr. Enright is a managing member of LCP, the sole general partner of LVP and LCA. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by LVP and LCA, except to the extent of his pecuniary interest therein.

Inozyme Pharma, Inc.

Report date April 19, 2022 · Filed April 21, 2022

Jointly reported with Longitude Capital Partners III, LLC, Longitude Venture Partners III, L.P., Tammenoms Bakker Juliet

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Longitude Venture Partners III, L.P.4,174,379 Reported balance After 2022-04-19 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2022-04-19 · Purchase · Acquired 1,355,000 · Balance 4,174,379

F1: These shares are held by Longitude Venture Partners III, L.P. ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and dispositive power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and dispositive power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Filing footnotes · ownership attribution and instrument terms

F1: These shares are held by Longitude Venture Partners III, L.P. ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and dispositive power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and dispositive power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Jazz Pharmaceuticals plc

Report date August 31, 2026 · Filed September 02, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Ordinary SharesSEC Table I · non-derivativeDirect21,278 Ending reported balance After 2026-08-31 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-08-31 · Tax withholding · Disposed 14 · Balance 22,970

F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

Row 2 · 2026-08-31 · Tax withholding · Disposed 1,692 · Balance 21,278

F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

Filing footnotes · ownership attribution and instrument terms

F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

Lexeo Therapeutics, Inc.

Report date November 07, 2023 · Filed November 10, 2023

Jointly reported with Longitude Capital Partners IV, LLC, Longitude Venture Partners IV, L.P., Tammenoms Bakker Juliet

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Longitude Venture Partners IV, L.P.2,567,100 Last balance in matching sequence After 2023-11-07 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rows

Row 1 · 2023-11-07 · Conversion · Acquired 1,793,429 · Balance 1,793,429

F1: Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date.

F2: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Mr. Enright and Ms. Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Row 2 · 2023-11-07 · Conversion · Acquired 319,126 · Balance 2,112,555

F3: Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.

F2: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Mr. Enright and Ms. Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Row 3 · 2023-11-07 · Purchase · Acquired 454,545 · Balance 2,567,100

F2: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Mr. Enright and Ms. Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Series A convertible preferred stockSEC Table II · derivative / convertible securityIndirectBy Longitude Venture Partners IV, L.P.0 Reported balance After 2023-11-07 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2023-11-07 · Conversion · Disposed 18,999,999 · Balance 0

F1: Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date.

F2: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Mr. Enright and Ms. Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Series B convertible preferred stockSEC Table II · derivative / convertible securityIndirectBy Longitude Venture Partners IV, L.P.0 Reported balance After 2023-11-07 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2023-11-07 · Conversion · Disposed 2,906,148 · Balance 0

F3: Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.

F2: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Mr. Enright and Ms. Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Filing footnotes · ownership attribution and instrument terms

F1: Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date.

F2: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Mr. Enright and Ms. Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

F3: Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.

Molecular Templates, Inc.

Report date August 28, 2020 · Filed September 01, 2020

Jointly reported with Longitude Capital Partners III, LLC, Longitude Venture Partners III, L.P., Tammenoms Bakker Juliet

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee Footnote0 Reported balance After 2020-08-28 transaction · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · 2020-08-28 · Sale · Disposed 2,447 · Balance 0

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.63 to $10.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

F2: These shares were held directly by Juliet Tammenoms Bakker ("Ms. Bakker").

Common StockSEC Table I · non-derivativeIndirectSee Footnote0 Reported balance After 2020-08-28 transaction · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · 2020-08-28 · Sale · Disposed 1,049 · Balance 0

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.63 to $10.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

F3: These shares were held by a trust. Ms. Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Ms. Bakker, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

Common StockSEC Table I · non-derivativeIndirectSee Footnote3,495 Reported balance Holding disclosure · report date 2020-08-28 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 3,495

F5: These shares are held by a limited partnership (the "Partnership") of which the general partner is a trust (the "Trust"). Mr. Enright is the Trustee of the Trust and may be deemed to share voting, investment and dispositive power over the shares held by the Partnership. Each of the Trust and Mr. Enright disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Enright, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

Common StockSEC Table I · non-derivativeIndirectBy Longitude Venture Partners III, L.P.3,199,035 Reported balance Holding disclosure · report date 2020-08-28 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 3,199,035

F4: These shares are held by Longitude Venture Partners III, L.P. ("Longitude Venture III"). This report is filed jointly by Longitude Capital Partners III, LLC ("Longitude Capital III"), Longitude Venture III, Patrick G. Enright ("Mr. Enright"), and Ms. Bakker. Longitude Capital III is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power over the shares held by Longitude Venture III. Mr. Enright and Ms. Bakker are the managing members of Longitude Capital III and may be deemed to share voting, investment and dispositive power over the shares held by Longitude Venture III. Each of Longitude Capital III, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.63 to $10.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

F2: These shares were held directly by Juliet Tammenoms Bakker ("Ms. Bakker").

F3: These shares were held by a trust. Ms. Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Ms. Bakker, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

F4: These shares are held by Longitude Venture Partners III, L.P. ("Longitude Venture III"). This report is filed jointly by Longitude Capital Partners III, LLC ("Longitude Capital III"), Longitude Venture III, Patrick G. Enright ("Mr. Enright"), and Ms. Bakker. Longitude Capital III is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power over the shares held by Longitude Venture III. Mr. Enright and Ms. Bakker are the managing members of Longitude Capital III and may be deemed to share voting, investment and dispositive power over the shares held by Longitude Venture III. Each of Longitude Capital III, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein.

F5: These shares are held by a limited partnership (the "Partnership") of which the general partner is a trust (the "Trust"). Mr. Enright is the Trustee of the Trust and may be deemed to share voting, investment and dispositive power over the shares held by the Partnership. Each of the Trust and Mr. Enright disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Enright, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

Tourmaline Bio, Inc.

Report date May 11, 2021 · Filed May 11, 2021

Jointly reported with Longitude Capital Partners III, LLC, Longitude Venture Partners III, L.P., Tammenoms Bakker Juliet

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Longitude Venture Partners III, L.P.3,220,775 Last balance in matching sequence After 2021-05-11 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 1 · 2021-05-11 · Conversion · Acquired 2,985,775 · Balance 2,985,775

F1: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date.

F2: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and investment power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and investment power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Row 2 · 2021-05-11 · Purchase · Acquired 235,000 · Balance 3,220,775

F3: On May 11, 2021, LVP III purchased 235,000 shares of Common Stock of the Issuer at a price of $17.00 per share pursuant to an underwritten public offering.

F2: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and investment power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and investment power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Series A Preferred StockSEC Table II · derivative / convertible securityIndirectBy Longitude Venture Partners III, L.P.0 Reported balance After 2021-05-11 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2021-05-11 · Conversion · Disposed 1,308,410 · Balance 0

F1: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date.

F2: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and investment power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and investment power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Series A-1 Preferred StockSEC Table II · derivative / convertible securityIndirectBy Longitude Venture Partners III, L.P.0 Reported balance After 2021-05-11 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2021-05-11 · Conversion · Disposed 1,271,027 · Balance 0

F1: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date.

F2: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and investment power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and investment power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Series B Preferred StockSEC Table II · derivative / convertible securityIndirectBy Longitude Venture Partners III, L.P.0 Reported balance After 2021-05-11 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2021-05-11 · Conversion · Disposed 406,338 · Balance 0

F1: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date.

F2: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and investment power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and investment power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date.

F2: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and investment power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and investment power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

F3: On May 11, 2021, LVP III purchased 235,000 shares of Common Stock of the Issuer at a price of $17.00 per share pursuant to an underwritten public offering.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Series A Preferred StockSEC Table II · derivative / convertible securityIndirectBy Longitude Venture Partners II, L.P.Not disclosed Reported balance Holding disclosure · report date 2020-06-11 · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · Balance Not disclosed

F1: The Series A Preferred Stock is convertible into Common Stock on a 1:1 basis and has no expiration date. Immediately prior to the consummation of the Issuer's initial public offering, all shares of Series A Preferred Stock will be converted into shares of Common Stock for no consideration.

F2: The securities are held of record by Longitude Venture Partners II, L.P. ("Longitude II"). Longitude Capital Partners II, LLC, ("LCP2"), the general partner of Longitude II, may be deemed to have voting, investment and dispositive power with respect to the shares held by Longitude II. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP2 and may be deemed to have voting, investment and dispositive power over the shares held by Longitude II. Each of LCP2, Mr. Enright and Ms. Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein.

Series B Preferred StockSEC Table II · derivative / convertible securityIndirectBy Longitude Venture Partners II, L.P.Not disclosed Reported balance Holding disclosure · report date 2020-06-11 · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · Balance Not disclosed

F3: The Series B Preferred Stock is convertible into Common Stock on a 1:1 basis and has no expiration date. Immediately prior to the consummation of the Issuer's initial public offering, all shares of Series B Preferred Stock will be converted into shares of Common Stock for no consideration.

F2: The securities are held of record by Longitude Venture Partners II, L.P. ("Longitude II"). Longitude Capital Partners II, LLC, ("LCP2"), the general partner of Longitude II, may be deemed to have voting, investment and dispositive power with respect to the shares held by Longitude II. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP2 and may be deemed to have voting, investment and dispositive power over the shares held by Longitude II. Each of LCP2, Mr. Enright and Ms. Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein.

Series C Preferred StockSEC Table II · derivative / convertible securityIndirectBy Longitude Venture Partners II, L.P.Not disclosed Reported balance Holding disclosure · report date 2020-06-11 · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · Balance Not disclosed

F4: The Series C Preferred Stock is convertible into Common Stock on a 1:1 basis and has no expiration date. Immediately prior to the consummation of the Issuer's initial public offering, all shares of Series C Preferred Stock will be converted into shares of Common Stock for no consideration.

F2: The securities are held of record by Longitude Venture Partners II, L.P. ("Longitude II"). Longitude Capital Partners II, LLC, ("LCP2"), the general partner of Longitude II, may be deemed to have voting, investment and dispositive power with respect to the shares held by Longitude II. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP2 and may be deemed to have voting, investment and dispositive power over the shares held by Longitude II. Each of LCP2, Mr. Enright and Ms. Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein.

Series D Preferred StockSEC Table II · derivative / convertible securityIndirectBy Longitude Venture Partners II, L.P.Not disclosed Reported balance Holding disclosure · report date 2020-06-11 · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · Balance Not disclosed

F5: The Series D Preferred Stock is convertible into Common Stock on a 1:1 basis and has no expiration date. Immediately prior to the consummation of the Issuer's initial public offering, all shares of Series D Preferred Stock will be converted into shares of Common Stock for no consideration.

F2: The securities are held of record by Longitude Venture Partners II, L.P. ("Longitude II"). Longitude Capital Partners II, LLC, ("LCP2"), the general partner of Longitude II, may be deemed to have voting, investment and dispositive power with respect to the shares held by Longitude II. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP2 and may be deemed to have voting, investment and dispositive power over the shares held by Longitude II. Each of LCP2, Mr. Enright and Ms. Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The Series A Preferred Stock is convertible into Common Stock on a 1:1 basis and has no expiration date. Immediately prior to the consummation of the Issuer's initial public offering, all shares of Series A Preferred Stock will be converted into shares of Common Stock for no consideration.

F2: The securities are held of record by Longitude Venture Partners II, L.P. ("Longitude II"). Longitude Capital Partners II, LLC, ("LCP2"), the general partner of Longitude II, may be deemed to have voting, investment and dispositive power with respect to the shares held by Longitude II. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP2 and may be deemed to have voting, investment and dispositive power over the shares held by Longitude II. Each of LCP2, Mr. Enright and Ms. Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein.

F3: The Series B Preferred Stock is convertible into Common Stock on a 1:1 basis and has no expiration date. Immediately prior to the consummation of the Issuer's initial public offering, all shares of Series B Preferred Stock will be converted into shares of Common Stock for no consideration.

F4: The Series C Preferred Stock is convertible into Common Stock on a 1:1 basis and has no expiration date. Immediately prior to the consummation of the Issuer's initial public offering, all shares of Series C Preferred Stock will be converted into shares of Common Stock for no consideration.

F5: The Series D Preferred Stock is convertible into Common Stock on a 1:1 basis and has no expiration date. Immediately prior to the consummation of the Issuer's initial public offering, all shares of Series D Preferred Stock will be converted into shares of Common Stock for no consideration.

Venus Concept Inc.

Report date November 07, 2019 · Filed November 08, 2019

Jointly reported with Longitude Capital Partners II, LLC, Longitude Venture Partners II, L.P.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Longitude Venture Partners II, L.P3,666,119 Reported balance Holding disclosure · report date 2019-11-07 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 3,666,119

F1: These shares were received in connection with the merger of a wholly-owned subsidiary of Restoration Robotics, Inc. with and into Venus Concept Ltd. (the "Merger") (i) 3,476,583 were received, in exchange for 2,192,736 shares, 3,287,420 shares and 548,185 shares of Series A Preferred Stock, Series B Preferred Stock and ordinary shares of Venus Concept Ltd., respectively and (ii) 189,535 were received, upon the conversion of the outstanding principal and any accrued and unpaid interest of three 8% Convertible Promissory Notes issued by Venus Concept Ltd., dated as of June 25, 2019, August 14, 2019 and August 21, 2019, in the original principal amounts of $300,000, $197,142.85 and $802,857.15, respectively.

F2: These shares are held directly by Longitude Venture Partners II, L.P. ("Longitude Venture II"). Longitude Capital Partners II, LLC ("Longitude Capital II") is the general partner of Longitude Venture II and may be deemed to have shared voting, investment and dispositive power with respect to these securities. Ms. Tammenoms Bakker, who is a member of the Issuer's board of directors, and Patrick G. Enright, are the managing members of Longitude Capital II (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of Longitude Capital II and the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Filing footnotes · ownership attribution and instrument terms

F1: These shares were received in connection with the merger of a wholly-owned subsidiary of Restoration Robotics, Inc. with and into Venus Concept Ltd. (the "Merger") (i) 3,476,583 were received, in exchange for 2,192,736 shares, 3,287,420 shares and 548,185 shares of Series A Preferred Stock, Series B Preferred Stock and ordinary shares of Venus Concept Ltd., respectively and (ii) 189,535 were received, upon the conversion of the outstanding principal and any accrued and unpaid interest of three 8% Convertible Promissory Notes issued by Venus Concept Ltd., dated as of June 25, 2019, August 14, 2019 and August 21, 2019, in the original principal amounts of $300,000, $197,142.85 and $802,857.15, respectively.

F2: These shares are held directly by Longitude Venture Partners II, L.P. ("Longitude Venture II"). Longitude Capital Partners II, LLC ("Longitude Capital II") is the general partner of Longitude Venture II and may be deemed to have shared voting, investment and dispositive power with respect to these securities. Ms. Tammenoms Bakker, who is a member of the Issuer's board of directors, and Patrick G. Enright, are the managing members of Longitude Capital II (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of Longitude Capital II and the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Vera Therapeutics, Inc.

Report date May 21, 2026 · Filed May 26, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.35 · Expires 2036-05-20Direct17,084 Reported balance After 2026-05-21 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-05-21 · Grant · Acquired 17,084 · Balance 17,084

F1: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.

Veradermics, Inc

Report date February 03, 2026 · Filed February 06, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee Footnote1,236,631 Reported balance After 2026-02-05 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 1 · 2026-02-05 · Conversion · Acquired 1,236,631 · Balance 1,236,631

F1: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.

F2: These shares are held by Longitude Venture Partners V, L.P. ("LVPV"). Longitude Capital Partners V, LLC ("LCPV"), is the general partner of LVPV and may be deemed to have voting, investment and dispositive power with respect to these shares. Juliet Tammenoms Bakker and the Reporting Person, a member of the board of directors of the Issuer, are the managing members of LCPV, and may each be deemed to share voting, investment and dispositive power with respect to these shares. Each of LCPV, Ms. Tammenoms Bakker and the Reporting Person disclaims beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.

Common StockSEC Table I · non-derivativeIndirectSee Footnote2,407,752 Reported balance After 2026-02-05 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 2 · 2026-02-05 · Conversion · Acquired 1,171,121 · Balance 2,407,752

F3: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.

F2: These shares are held by Longitude Venture Partners V, L.P. ("LVPV"). Longitude Capital Partners V, LLC ("LCPV"), is the general partner of LVPV and may be deemed to have voting, investment and dispositive power with respect to these shares. Juliet Tammenoms Bakker and the Reporting Person, a member of the board of directors of the Issuer, are the managing members of LCPV, and may each be deemed to share voting, investment and dispositive power with respect to these shares. Each of LCPV, Ms. Tammenoms Bakker and the Reporting Person disclaims beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.

Common StockSEC Table I · non-derivativeIndirectSee Footnote1,171,121 Reported balance After 2026-02-05 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 3 · 2026-02-05 · Conversion · Acquired 1,171,121 · Balance 1,171,121

F3: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.

F4: These shares are held by Longitude 103.8 East, L.P. ("L103"). Longitude 103.8 East Partners, LLC ("L103P") is the general partner of L103 and may be deemed to have voting, investment and dispositive power with respect to these shares. Juliet Tammenoms Bakker and the Reporting Person, a member of the board of directors of the Issuer, are the managing members of L103P, and may each be deemed to share voting, investment and dispositive power with respect to these shares. Each of L103P, Ms. Tammenoms Bakker and the Reporting Person disclaims beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.

Common StockSEC Table I · non-derivativeIndirectSee Footnote2,600,399 Reported balance After 2026-02-05 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 4 · 2026-02-05 · Purchase · Acquired 192,647 · Balance 2,600,399

F2: These shares are held by Longitude Venture Partners V, L.P. ("LVPV"). Longitude Capital Partners V, LLC ("LCPV"), is the general partner of LVPV and may be deemed to have voting, investment and dispositive power with respect to these shares. Juliet Tammenoms Bakker and the Reporting Person, a member of the board of directors of the Issuer, are the managing members of LCPV, and may each be deemed to share voting, investment and dispositive power with respect to these shares. Each of LCPV, Ms. Tammenoms Bakker and the Reporting Person disclaims beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.

Common StockSEC Table I · non-derivativeIndirectSee Footnote2,053,474 Reported balance After 2026-02-05 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 5 · 2026-02-05 · Purchase · Acquired 882,353 · Balance 2,053,474

F4: These shares are held by Longitude 103.8 East, L.P. ("L103"). Longitude 103.8 East Partners, LLC ("L103P") is the general partner of L103 and may be deemed to have voting, investment and dispositive power with respect to these shares. Juliet Tammenoms Bakker and the Reporting Person, a member of the board of directors of the Issuer, are the managing members of L103P, and may each be deemed to share voting, investment and dispositive power with respect to these shares. Each of L103P, Ms. Tammenoms Bakker and the Reporting Person disclaims beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.

Series B Convertible Preferred StockSEC Table II · derivative / convertible securityIndirectSee Footnote0 Reported balance After 2026-02-05 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2026-02-05 · Conversion · Disposed 1,236,631 · Balance 0

F1: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.

Series C Convertible Preferred StockSEC Table II · derivative / convertible securityIndirectSee Footnote0 Reported balance After 2026-02-05 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2026-02-05 · Conversion · Disposed 1,171,121 · Balance 0

F3: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.

Series C Convertible Preferred StockSEC Table II · derivative / convertible securityIndirectSee Footnote0 Reported balance After 2026-02-05 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2026-02-05 · Conversion · Disposed 1,171,121 · Balance 0

F3: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2036-02-03Direct45,131 Reported balance After 2026-02-03 transaction · row 9 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 9 · 2026-02-03 · Grant · Acquired 45,131 · Balance 45,131

F5: This option shall be fully vested and exercisable on February 3, 2027, the first anniversary of the vesting commencement date.

Filing footnotes · ownership attribution and instrument terms

F1: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.

F2: These shares are held by Longitude Venture Partners V, L.P. ("LVPV"). Longitude Capital Partners V, LLC ("LCPV"), is the general partner of LVPV and may be deemed to have voting, investment and dispositive power with respect to these shares. Juliet Tammenoms Bakker and the Reporting Person, a member of the board of directors of the Issuer, are the managing members of LCPV, and may each be deemed to share voting, investment and dispositive power with respect to these shares. Each of LCPV, Ms. Tammenoms Bakker and the Reporting Person disclaims beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.

F3: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.

F4: These shares are held by Longitude 103.8 East, L.P. ("L103"). Longitude 103.8 East Partners, LLC ("L103P") is the general partner of L103 and may be deemed to have voting, investment and dispositive power with respect to these shares. Juliet Tammenoms Bakker and the Reporting Person, a member of the board of directors of the Issuer, are the managing members of L103P, and may each be deemed to share voting, investment and dispositive power with respect to these shares. Each of L103P, Ms. Tammenoms Bakker and the Reporting Person disclaims beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.

F5: This option shall be fully vested and exercisable on February 3, 2027, the first anniversary of the vesting commencement date.

Zenas BioPharma, Inc.

Report date June 15, 2026 · Filed June 17, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.71 · Expires 2036-06-15Direct18,500 Reported balance After 2026-06-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-06-15 · Grant · Acquired 18,500 · Balance 18,500

F1: The option vests as to 100% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, subject to continued service.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests as to 100% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, subject to continued service.

Past disclosures · reporting ended (8)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Section 16 reporting ended · disclosed 2020-11-18. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee footnote1,750,877 Reported balance After 2020-11-16 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2020-11-16 · Other · Disposed 850,000 · Balance 1,750,877

F1: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners III, L.P. ("Longitude Venture III") to its general and limited partners.

F2: These shares are held directly by Longitude Venture III. Longitude Capital Partners III, LLC ("Longitude Capital III") is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of Longitude Capital III (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of Longitude Capital III and the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Common StockSEC Table I · non-derivativeIndirectSee footnote2,973 Reported balance After 2020-11-16 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2020-11-16 · Other · Acquired 2,973 · Balance 2,973

F3: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Capital III to its members.

F4: These shares are held by a limited partnership (the "Partnership") of which the general partner is a trust (the "Trust"). Mr. Enright is the Trustee of the Trust and may be deemed to share voting, investment and dispositive power over the shares held by the Partnership. Each of the Trust and Mr. Enright disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Enright, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

Common StockSEC Table I · non-derivativeIndirectSee footnote2,080 Reported balance After 2020-11-16 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2020-11-16 · Other · Acquired 2,080 · Balance 2,080

F3: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Capital III to its members.

F5: These shares are held by a trust. Ms. Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Ms. Bakker, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

Common StockSEC Table I · non-derivativeIndirectSee footnote891 Reported balance After 2020-11-16 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 4 · 2020-11-16 · Other · Acquired 891 · Balance 891

F3: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Capital III to its members.

F6: These shares are held directly by Ms. Bakker.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners III, L.P. ("Longitude Venture III") to its general and limited partners.

F2: These shares are held directly by Longitude Venture III. Longitude Capital Partners III, LLC ("Longitude Capital III") is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of Longitude Capital III (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of Longitude Capital III and the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

F3: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Capital III to its members.

F4: These shares are held by a limited partnership (the "Partnership") of which the general partner is a trust (the "Trust"). Mr. Enright is the Trustee of the Trust and may be deemed to share voting, investment and dispositive power over the shares held by the Partnership. Each of the Trust and Mr. Enright disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Enright, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

F5: These shares are held by a trust. Ms. Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Ms. Bakker, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

F6: These shares are held directly by Ms. Bakker.

Aimmune Therapeutics, Inc.

Report date October 10, 2020 · Filed October 14, 2020

Section 16 reporting ended · disclosed 2020-10-14. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common Stock, $0.0001 par valueSEC Table I · non-derivativeDirect0 Reported balance After 2020-10-10 transaction · row 1 Sequence does not reconcile; account continuity is unresolved.
1 source row

Row 1 · 2020-10-10 · Other · Disposed 70,561 · Balance 0

Common Stock, $0.0001 par valueSEC Table I · non-derivativeDirect0 Reported balance After 2020-10-13 transaction · row 3 Sequence does not reconcile; account continuity is unresolved.
1 source row

Row 3 · 2020-10-13 · Disposition to issuer · Disposed 7,840 · Balance 0

F2: Disposed of to SPN MergerSub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated August 29, 2020, by and between the Issuer, Societes des Produits Nestle S.A., ("Nestle"), and Merger Sub (the "Merger Agreement"), commenced a tender offer to acquire any and all of the outstanding shares of the Issuer's common stock (other than those shares owned by Nestle and its affiliates) at a purchase price of $34.50 per share (the "Offer Price").

F3: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") vested in full, terminated, and was converted into the right to receive a cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of common stock subject to the RSU.

Common Stock, $0.0001 par valueSEC Table I · non-derivativeIndirectBy: LCP20 Reported balance After 2020-10-10 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 2 · 2020-10-10 · Other · Disposed 91,697 · Balance 0

F1: Reflects shares held by Longitude Capital Partners II, LLC ("LCP2"). The Reporting Person is a managing member of LCP2 and in his capacity as such may be deemed to share voting and investment power over the shares held by LCP2. The Reporting Person disclaims beneficial ownership over these securities and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.14Direct0 Reported balance After 2020-10-13 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2020-10-13 · Disposition to issuer · Disposed 65,849 · Balance 0

F4: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.29Direct0 Reported balance After 2020-10-13 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2020-10-13 · Disposition to issuer · Disposed 52,421 · Balance 0

F4: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.40Direct0 Reported balance After 2020-10-13 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2020-10-13 · Disposition to issuer · Disposed 19,755 · Balance 0

F4: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.26Direct0 Reported balance After 2020-10-13 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2020-10-13 · Disposition to issuer · Disposed 17,500 · Balance 0

F4: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.79Direct0 Reported balance After 2020-10-13 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2020-10-13 · Disposition to issuer · Disposed 7,500 · Balance 0

F4: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.90Direct0 Reported balance After 2020-10-13 transaction · row 9 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 9 · 2020-10-13 · Disposition to issuer · Disposed 11,432 · Balance 0

F4: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.11Direct0 Reported balance After 2020-10-13 transaction · row 10 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 10 · 2020-10-13 · Disposition to issuer · Disposed 15,398 · Balance 0

F4: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects shares held by Longitude Capital Partners II, LLC ("LCP2"). The Reporting Person is a managing member of LCP2 and in his capacity as such may be deemed to share voting and investment power over the shares held by LCP2. The Reporting Person disclaims beneficial ownership over these securities and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

F2: Disposed of to SPN MergerSub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated August 29, 2020, by and between the Issuer, Societes des Produits Nestle S.A., ("Nestle"), and Merger Sub (the "Merger Agreement"), commenced a tender offer to acquire any and all of the outstanding shares of the Issuer's common stock (other than those shares owned by Nestle and its affiliates) at a purchase price of $34.50 per share (the "Offer Price").

F3: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") vested in full, terminated, and was converted into the right to receive a cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of common stock subject to the RSU.

F4: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.

Section 16 reporting ended · disclosed 2017-12-12. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy LVP2,276,222 Reported balance After 2017-12-08 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2017-12-08 · Sale · Disposed 980,350 · Balance 2,276,222

F1: This report is filed jointly by Longitude Capital Partners, LLC ("LCP"), Longitude Venture Partners, L.P. ("LVP"), Longitude Capital Associates, L.P. ("LCA"), Patrick G. Enright ("Enright") and Juliet Tammenoms Bakker ("Bakker"). LCP is the general partner of LVP and LCA, has the power to vote and dispose of the securities of the Issuer held by each of LVP and LCA, and may be deemed to have beneficial ownership of such securities. Each of Enright and Bakker is a managing member of LCP, has the power to vote and dispose of the securities of the Issuer held by each of LVP and LCA, and may be deemed to have beneficial ownership of such securities. Each of LCP, Enright and Bakker disclaims beneficial ownership of the securities of the Issuer held by LVP and LCA except to the extent of their respective pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy LCA45,620 Reported balance After 2017-12-08 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2017-12-08 · Sale · Disposed 19,650 · Balance 45,620

F1: This report is filed jointly by Longitude Capital Partners, LLC ("LCP"), Longitude Venture Partners, L.P. ("LVP"), Longitude Capital Associates, L.P. ("LCA"), Patrick G. Enright ("Enright") and Juliet Tammenoms Bakker ("Bakker"). LCP is the general partner of LVP and LCA, has the power to vote and dispose of the securities of the Issuer held by each of LVP and LCA, and may be deemed to have beneficial ownership of such securities. Each of Enright and Bakker is a managing member of LCP, has the power to vote and dispose of the securities of the Issuer held by each of LVP and LCA, and may be deemed to have beneficial ownership of such securities. Each of LCP, Enright and Bakker disclaims beneficial ownership of the securities of the Issuer held by LVP and LCA except to the extent of their respective pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: This report is filed jointly by Longitude Capital Partners, LLC ("LCP"), Longitude Venture Partners, L.P. ("LVP"), Longitude Capital Associates, L.P. ("LCA"), Patrick G. Enright ("Enright") and Juliet Tammenoms Bakker ("Bakker"). LCP is the general partner of LVP and LCA, has the power to vote and dispose of the securities of the Issuer held by each of LVP and LCA, and may be deemed to have beneficial ownership of such securities. Each of Enright and Bakker is a managing member of LCP, has the power to vote and dispose of the securities of the Issuer held by each of LVP and LCA, and may be deemed to have beneficial ownership of such securities. Each of LCP, Enright and Bakker disclaims beneficial ownership of the securities of the Issuer held by LVP and LCA except to the extent of their respective pecuniary interest therein.

Eargo, Inc.

Report date April 14, 2021 · Filed April 16, 2021

Jointly reported with Longitude Venture Partners IV, L.P., Longitude Capital Partners IV, LLC

Section 16 reporting ended · disclosed 2021-04-16. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect2,918,691 Reported balance After 2021-04-14 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2021-04-14 · Other · Disposed 1,000,000 · Balance 2,918,691

F1: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners IV, L.P. ("LVP4") to its general and limited partners, pursuant to a Rule 10b5-1 trading plan.

F2: These shares are held directly by LVP4. Longitude Capital Partners IV, LLC ("LCP4") is the general partner of LVP4 and may be deemed to have voting, investment and dispositive power over the shares held by LVP4. Juliet Tammenoms Bakker, a member of the Issuer's board of directors, and Patrick G. Enright are managing members of LCP4 (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to the shares held by LVP4. Each of LCP4 and the Managers disclaims beneficial ownership of the shares held by LVP4 and this report shall not be deemed an admission that any of them is the beneficial owner of such shares for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

F3: (Continued from footnote 2) Juliet Tammenoms Bakker, a managing member of LCP4, currently serves on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer.

Common StockSEC Table I · non-derivativeIndirectSee Footnote5,012 Reported balance After 2021-04-14 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2021-04-14 · Other · Acquired 5,012 · Balance 5,012

F4: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP4 to its members.

F5: These shares are held by a limited partnership (the "Partnership") of which the general partner is a trust (the "Trust"). Mr. Enright is the Trustee of the Trust and may be deemed to share voting, investment and dispositive power over the shares held by the Partnership. Each of the Trust and Mr. Enright disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Enright, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners IV, L.P. ("LVP4") to its general and limited partners, pursuant to a Rule 10b5-1 trading plan.

F2: These shares are held directly by LVP4. Longitude Capital Partners IV, LLC ("LCP4") is the general partner of LVP4 and may be deemed to have voting, investment and dispositive power over the shares held by LVP4. Juliet Tammenoms Bakker, a member of the Issuer's board of directors, and Patrick G. Enright are managing members of LCP4 (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to the shares held by LVP4. Each of LCP4 and the Managers disclaims beneficial ownership of the shares held by LVP4 and this report shall not be deemed an admission that any of them is the beneficial owner of such shares for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

F3: (Continued from footnote 2) Juliet Tammenoms Bakker, a managing member of LCP4, currently serves on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer.

F4: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP4 to its members.

F5: These shares are held by a limited partnership (the "Partnership") of which the general partner is a trust (the "Trust"). Mr. Enright is the Trustee of the Trust and may be deemed to share voting, investment and dispositive power over the shares held by the Partnership. Each of the Trust and Mr. Enright disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Enright, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

Section 16 reporting ended · disclosed 2017-07-27. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Longitude Venture Partners II, L.P.2,270,946 Last balance in matching sequence After 2017-07-25 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 1 · 2017-07-25 · Conversion · Acquired 2,055,946 · Balance 2,055,946

F1: The Series C Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2: This Form 4 is filed jointly by Longitude Capital Partners II, LLC ("Longitude Capital II"), Longitude Venture Partners II, L.P. ("Longitude Venture II"), Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom shared beneficial ownership of more than 10% of the capital stock of the Issuer as of the date of the transactions reported in this Form 4. Longitude Capital II is the general partner of Longitude Venture II and may be deemed to share voting and investment power over the shares held by Longitude Venture II. Mr. Enright and Ms. Bakker are the managing members of Longitude Capital II and may be deemed to share voting and investment power over the shares held by Longitude Venture II. Each of Longitude Capital II, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein.

F3: Longitude Venture II acquired 215,000 shares of Common Stock in the Issuer's initial public offering.

Row 2 · 2017-07-25 · Purchase · Acquired 215,000 · Balance 2,270,946

F2: This Form 4 is filed jointly by Longitude Capital Partners II, LLC ("Longitude Capital II"), Longitude Venture Partners II, L.P. ("Longitude Venture II"), Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom shared beneficial ownership of more than 10% of the capital stock of the Issuer as of the date of the transactions reported in this Form 4. Longitude Capital II is the general partner of Longitude Venture II and may be deemed to share voting and investment power over the shares held by Longitude Venture II. Mr. Enright and Ms. Bakker are the managing members of Longitude Capital II and may be deemed to share voting and investment power over the shares held by Longitude Venture II. Each of Longitude Capital II, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein.

F3: Longitude Venture II acquired 215,000 shares of Common Stock in the Issuer's initial public offering.

Series C Preferred StockSEC Table II · derivative / convertible securityIndirectBy Longitude Venture Partners II, L.P.0 Reported balance After 2017-07-25 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2017-07-25 · Conversion · Disposed 10,707,985 · Balance 0

F1: The Series C Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2: This Form 4 is filed jointly by Longitude Capital Partners II, LLC ("Longitude Capital II"), Longitude Venture Partners II, L.P. ("Longitude Venture II"), Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom shared beneficial ownership of more than 10% of the capital stock of the Issuer as of the date of the transactions reported in this Form 4. Longitude Capital II is the general partner of Longitude Venture II and may be deemed to share voting and investment power over the shares held by Longitude Venture II. Mr. Enright and Ms. Bakker are the managing members of Longitude Capital II and may be deemed to share voting and investment power over the shares held by Longitude Venture II. Each of Longitude Capital II, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein.

F3: Longitude Venture II acquired 215,000 shares of Common Stock in the Issuer's initial public offering.

Filing footnotes · ownership attribution and instrument terms

F1: The Series C Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2: This Form 4 is filed jointly by Longitude Capital Partners II, LLC ("Longitude Capital II"), Longitude Venture Partners II, L.P. ("Longitude Venture II"), Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom shared beneficial ownership of more than 10% of the capital stock of the Issuer as of the date of the transactions reported in this Form 4. Longitude Capital II is the general partner of Longitude Venture II and may be deemed to share voting and investment power over the shares held by Longitude Venture II. Mr. Enright and Ms. Bakker are the managing members of Longitude Capital II and may be deemed to share voting and investment power over the shares held by Longitude Venture II. Each of Longitude Capital II, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein.

F3: Longitude Venture II acquired 215,000 shares of Common Stock in the Issuer's initial public offering.

Section 16 reporting ended · disclosed 2026-02-06. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class A Common StockSEC Table I · non-derivativeIndirectHeld by Longitude Prime Fund, L.P.0 Reported balance After 2026-02-04 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2026-02-04 · Sale · Disposed 49,000 · Balance 0

F1: The securities are held directly by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP"), the general partner of LPF, may be deemed to have voting and dispositive power with respect to the shares held by LPF. Mr. Enright and Ms. Tammenoms Bakker are the managing members of LPP and may be deemed to have voting and dispositive power over the shares held by LPF. LPP and each of Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.

Class A Common StockSEC Table I · non-derivativeIndirectHeld by Longitude Venture Partners II, L.P.4,029,245 Reported balance Holding disclosure · report date 2026-02-04 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 4,029,245

F2: The securities are held directly by LVPII. Longitude Capital Partners II, LLC, ("LCPII"), the general partner of LVPII, may be deemed to have voting and dispositive power with respect to the shares held by LVPII. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCPII and may be deemed to share voting and dispositive power over the shares held by LVPII. Each of LCPII, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The securities are held directly by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP"), the general partner of LPF, may be deemed to have voting and dispositive power with respect to the shares held by LPF. Mr. Enright and Ms. Tammenoms Bakker are the managing members of LPP and may be deemed to have voting and dispositive power over the shares held by LPF. LPP and each of Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.

F2: The securities are held directly by LVPII. Longitude Capital Partners II, LLC, ("LCPII"), the general partner of LVPII, may be deemed to have voting and dispositive power with respect to the shares held by LVPII. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCPII and may be deemed to share voting and dispositive power over the shares held by LVPII. Each of LCPII, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein.

Section 16 reporting ended · disclosed 2022-04-29. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee footnote0 Reported balance After 2022-04-27 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2022-04-27 · Other · Disposed 175,000 · Balance 0

F1: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Prime Fund, L.P. ("LPF") to its general and limited partners.

F2: The securities are held directly by LPF. Longitude Prime Partners, LLC ("LPP"), the general partner of LPF, may be deemed to have voting and investment power with respect to the shares held by LPF. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LPP and may be deemed to share voting, investment and dispositive power over such securities. Each of LPP, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

Common StockSEC Table I · non-derivativeIndirectSee footnote0 Reported balance After 2022-04-27 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2022-04-27 · Other · Disposed 1,964,771 · Balance 0

F3: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners III, L.P. ("LVP III") to its general and limited partners.

F4: These securities are held directly by LVP III. Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting, investment and dispositive power with respect to such securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP III and may be deemed to share voting, investment and dispositive power over such securities. Each of LCP III, Mr. Enright, and Ms. Tammenoms Bakker disclaim beneficial ownership over such securities except to the extent of their respective pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

Common StockSEC Table I · non-derivativeIndirectSee footnote5,023 Reported balance After 2022-04-27 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2022-04-27 · Other · Acquired 5,023 · Balance 5,023

F5: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP III to its members.

F6: These shares are held directly by Juliet Tammenoms Bakker.

Common StockSEC Table I · non-derivativeIndirectSee footnote2,152 Reported balance After 2022-04-27 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 4 · 2022-04-27 · Other · Acquired 2,152 · Balance 2,152

F5: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP III to its members.

F7: These shares are held by a trust. Juliet Tammenoms Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Tammenoms Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectSee footnote7,175 Reported balance After 2022-04-27 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 5 · 2022-04-27 · Other · Acquired 7,175 · Balance 7,175

F5: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP III to its members.

F8: These shares are held directly by Patrick G. Enright.

Common StockSEC Table I · non-derivativeIndirectSee footnote5,611 Reported balance After 2022-04-27 transaction · row 6 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 6 · 2022-04-27 · Other · Acquired 588 · Balance 5,611

F9: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LPP to its members

F6: These shares are held directly by Juliet Tammenoms Bakker.

Common StockSEC Table I · non-derivativeIndirectSee footnote2,404 Reported balance After 2022-04-27 transaction · row 7 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 7 · 2022-04-27 · Other · Acquired 252 · Balance 2,404

F9: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LPP to its members

F7: These shares are held by a trust. Juliet Tammenoms Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Tammenoms Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectSee footnote8,015 Reported balance After 2022-04-27 transaction · row 8 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 8 · 2022-04-27 · Other · Acquired 840 · Balance 8,015

F9: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LPP to its members

F8: These shares are held directly by Patrick G. Enright.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Prime Fund, L.P. ("LPF") to its general and limited partners.

F2: The securities are held directly by LPF. Longitude Prime Partners, LLC ("LPP"), the general partner of LPF, may be deemed to have voting and investment power with respect to the shares held by LPF. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LPP and may be deemed to share voting, investment and dispositive power over such securities. Each of LPP, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

F3: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners III, L.P. ("LVP III") to its general and limited partners.

F4: These securities are held directly by LVP III. Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting, investment and dispositive power with respect to such securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP III and may be deemed to share voting, investment and dispositive power over such securities. Each of LCP III, Mr. Enright, and Ms. Tammenoms Bakker disclaim beneficial ownership over such securities except to the extent of their respective pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

F5: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP III to its members.

F6: These shares are held directly by Juliet Tammenoms Bakker.

F7: These shares are held by a trust. Juliet Tammenoms Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Tammenoms Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein.

F8: These shares are held directly by Patrick G. Enright.

F9: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LPP to its members

Section 16 reporting ended · disclosed 2018-07-03. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectLongitude Venture Partners II, L.P.2,888,155 Last balance in matching sequence After 2018-07-02 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 1 · 2018-07-02 · Conversion · Acquired 2,431,511 · Balance 2,431,511

F1: Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date. Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock.

F2: These shares are held directly by Longitude Venture Partners II, L.P. ("Longitude II"). This statement is filed jointly by Longitude Capital Partners II, LLC ("LCP2"), Longitude II, Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer. LCP2 is the general partner of Longitude II and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II. Mr. Enright and Ms. Bakker are the managing members of LCP2 and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II.

F3: Each of LCP2, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein, and the filing of this statement shall not be deemed an admission that any such Reporting Person is a beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Row 2 · 2018-07-02 · Conversion · Acquired 456,644 · Balance 2,888,155

F1: Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date. Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock.

F2: These shares are held directly by Longitude Venture Partners II, L.P. ("Longitude II"). This statement is filed jointly by Longitude Capital Partners II, LLC ("LCP2"), Longitude II, Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer. LCP2 is the general partner of Longitude II and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II. Mr. Enright and Ms. Bakker are the managing members of LCP2 and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II.

F3: Each of LCP2, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein, and the filing of this statement shall not be deemed an admission that any such Reporting Person is a beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Common StockSEC Table I · non-derivativeIndirectLongitude Venture Partners II, L.P3,019,734 Reported balance After 2018-07-02 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2018-07-02 · Purchase · Acquired 131,579 · Balance 3,019,734

F2: These shares are held directly by Longitude Venture Partners II, L.P. ("Longitude II"). This statement is filed jointly by Longitude Capital Partners II, LLC ("LCP2"), Longitude II, Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer. LCP2 is the general partner of Longitude II and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II. Mr. Enright and Ms. Bakker are the managing members of LCP2 and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II.

F3: Each of LCP2, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein, and the filing of this statement shall not be deemed an admission that any such Reporting Person is a beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Series C Convertible Preferred StockSEC Table II · derivative / convertible securityIndirectBy Longitude Venture Partners II, L.P.0 Reported balance After 2018-07-02 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2018-07-02 · Conversion · Disposed 9,677,419 · Balance 0

F1: Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date. Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock.

F2: These shares are held directly by Longitude Venture Partners II, L.P. ("Longitude II"). This statement is filed jointly by Longitude Capital Partners II, LLC ("LCP2"), Longitude II, Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer. LCP2 is the general partner of Longitude II and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II. Mr. Enright and Ms. Bakker are the managing members of LCP2 and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II.

F3: Each of LCP2, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein, and the filing of this statement shall not be deemed an admission that any such Reporting Person is a beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Series D Convertible Preferred StockSEC Table II · derivative / convertible securityIndirectBy Longitude Venture Partners II, L.P.0 Reported balance After 2018-07-02 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2018-07-02 · Conversion · Disposed 1,817,447 · Balance 0

F1: Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date. Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock.

F2: These shares are held directly by Longitude Venture Partners II, L.P. ("Longitude II"). This statement is filed jointly by Longitude Capital Partners II, LLC ("LCP2"), Longitude II, Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer. LCP2 is the general partner of Longitude II and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II. Mr. Enright and Ms. Bakker are the managing members of LCP2 and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II.

F3: Each of LCP2, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein, and the filing of this statement shall not be deemed an admission that any such Reporting Person is a beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date. Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock.

F2: These shares are held directly by Longitude Venture Partners II, L.P. ("Longitude II"). This statement is filed jointly by Longitude Capital Partners II, LLC ("LCP2"), Longitude II, Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer. LCP2 is the general partner of Longitude II and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II. Mr. Enright and Ms. Bakker are the managing members of LCP2 and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II.

F3: Each of LCP2, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein, and the filing of this statement shall not be deemed an admission that any such Reporting Person is a beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
April 14, 2021 Filed Apr 16, 2021 01:00 UTC Eargo, Inc. EAR · Entity 94112 OtherCommon Stock 5,012 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-016024 · doc4.xml · nonDerivative · entry 2

Longitude Venture Partners IV, L.P. · CIK 0001787456 · 10% owner

Longitude Capital Partners IV, LLC · CIK 0001829169 · 10% owner

ENRIGHT PATRICK G · CIK 0001253886 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,012

F4 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP4 to its members.

F5 · ownership.nature: These shares are held by a limited partnership (the "Partnership") of which the general partner is a trust (the "Trust"). Mr. Enright is the Trustee of the Trust and may be deemed to share voting, investment and dispositive power over the shares held by the Partnership. Each of the Trust and Mr. Enright disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Enright, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

Read SEC document
April 14, 2021 Filed Apr 16, 2021 01:00 UTC Eargo, Inc. EAR · Entity 94112 OtherCommon Stock 1,000,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-016024 · doc4.xml · nonDerivative · entry 1

Longitude Venture Partners IV, L.P. · CIK 0001787456 · 10% owner

Longitude Capital Partners IV, LLC · CIK 0001829169 · 10% owner

ENRIGHT PATRICK G · CIK 0001253886 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,918,691

F1 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners IV, L.P. ("LVP4") to its general and limited partners, pursuant to a Rule 10b5-1 trading plan.

F2 · ownership.direct: These shares are held directly by LVP4. Longitude Capital Partners IV, LLC ("LCP4") is the general partner of LVP4 and may be deemed to have voting, investment and dispositive power over the shares held by LVP4. Juliet Tammenoms Bakker, a member of the Issuer's board of directors, and Patrick G. Enright are managing members of LCP4 (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to the shares held by LVP4. Each of LCP4 and the Managers disclaims beneficial ownership of the shares held by LVP4 and this report shall not be deemed an admission that any of them is the beneficial owner of such shares for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

F3 · ownership.direct: (Continued from footnote 2) Juliet Tammenoms Bakker, a managing member of LCP4, currently serves on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer.

Read SEC document
December 31, 2020 Filed Jan 5, 2021 16:31 UTC Aptinyx Inc. APTX · Entity 120922 GrantStock Option (Right to Buy) · Derivative 8,149 $2.22 Strike: $3.46 $18,123.38
Disclosure

SEC source: 0001415889-21-000087 · form4-01052021_040102.xml · derivative · entry 1

ENRIGHT PATRICK G · CIK 0001253886 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,149

Underlying: Common Stock · 8,149 shares

Expires 2030-12-30

F1 · shares: The option award was issued to the Reporting Person, who elected to take equity awards in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.

F2 · derivative.exercise_date: This option is fully vested at time of grant.

Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:11 UTC 89bio, Inc. ETNB · Entity 73682 OtherCommon Stock 891 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-031489 · doc4.xml · nonDerivative · entry 4

Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner

Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner

Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner

ENRIGHT PATRICK G · CIK 0001253886 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 891

F3 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Capital III to its members.

F6 · ownership.nature: These shares are held directly by Ms. Bakker.

Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:11 UTC 89bio, Inc. ETNB · Entity 73682 OtherCommon Stock 2,080 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-031489 · doc4.xml · nonDerivative · entry 3

Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner

Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner

Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner

ENRIGHT PATRICK G · CIK 0001253886 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,080

F3 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Capital III to its members.

F5 · ownership.nature: These shares are held by a trust. Ms. Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Ms. Bakker, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:11 UTC 89bio, Inc. ETNB · Entity 73682 OtherCommon Stock 2,973 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-031489 · doc4.xml · nonDerivative · entry 2

Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner

Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner

Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner

ENRIGHT PATRICK G · CIK 0001253886 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,973

F3 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Capital III to its members.

F4 · ownership.nature: These shares are held by a limited partnership (the "Partnership") of which the general partner is a trust (the "Trust"). Mr. Enright is the Trustee of the Trust and may be deemed to share voting, investment and dispositive power over the shares held by the Partnership. Each of the Trust and Mr. Enright disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Enright, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:11 UTC 89bio, Inc. ETNB · Entity 73682 OtherCommon Stock 850,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-031489 · doc4.xml · nonDerivative · entry 1

Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner

Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner

Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner

ENRIGHT PATRICK G · CIK 0001253886 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,750,877

F1 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners III, L.P. ("Longitude Venture III") to its general and limited partners.

F2 · ownership.nature: These shares are held directly by Longitude Venture III. Longitude Capital Partners III, LLC ("Longitude Capital III") is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of Longitude Capital III (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of Longitude Capital III and the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Read SEC document
November 12, 2020 Filed Nov 13, 2020 21:56 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 SaleOrdinary Shares 1,623 $147.61 $239,574.60
Disclosure

SEC source: 0001765581-20-000120 · edgardoc.xml · nonDerivative · entry 3

ENRIGHT PATRICK G · CIK 0001253886 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,368

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.56 to $147.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
November 12, 2020 Filed Nov 13, 2020 21:56 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 SaleOrdinary Shares 5,083 $147.00 $747,217.27
Disclosure

SEC source: 0001765581-20-000120 · edgardoc.xml · nonDerivative · entry 2

ENRIGHT PATRICK G · CIK 0001253886 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,991

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.559 to $147.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
November 12, 2020 Filed Nov 13, 2020 21:56 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 SaleOrdinary Shares 3,223 $145.81 $469,946.27
Disclosure

SEC source: 0001765581-20-000120 · edgardoc.xml · nonDerivative · entry 1

ENRIGHT PATRICK G · CIK 0001253886 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,074

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $145.36 to $146.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
November 02, 2020 Filed Nov 5, 2020 00:26 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 Exercise / conversionPhantom Stock · Derivative 9,929 Not disclosed Not disclosed
Disclosure

SEC source: 0001765581-20-000103 · edgardoc.xml · derivative · entry 2

ENRIGHT PATRICK G · CIK 0001253886 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 9,929 shares

Expires 2020-11-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On November 2, 2020, the Reporting Person's 9,929 phantom stock rights under the Issuer's Amended and Restated Directors Deferred Compensation Plan were settled for an equal number of the Issuer's ordinary shares.

F1 · price: On November 2, 2020, the Reporting Person's 9,929 phantom stock rights under the Issuer's Amended and Restated Directors Deferred Compensation Plan were settled for an equal number of the Issuer's ordinary shares.

Read SEC document
November 02, 2020 Filed Nov 5, 2020 00:26 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 Exercise / conversionOrdinary Shares 9,929 Not disclosed Not disclosed
Disclosure

SEC source: 0001765581-20-000103 · edgardoc.xml · nonDerivative · entry 1

ENRIGHT PATRICK G · CIK 0001253886 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,297

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On November 2, 2020, the Reporting Person's 9,929 phantom stock rights under the Issuer's Amended and Restated Directors Deferred Compensation Plan were settled for an equal number of the Issuer's ordinary shares.

Read SEC document
October 20, 2020 Filed Oct 23, 2020 00:24 UTC Eargo, Inc. EAR · Entity 94112 ConversionSeries E Preferred Stock · Derivative 3,685,358 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-029109 · doc4.xml · derivative · entry 3

Longitude Venture Partners IV, L.P. · CIK 0001787456 · 10% owner

ENRIGHT PATRICK G · CIK 0001253886 · 10% owner

Longitude Capital Partners IV, LLC · CIK 0001829169 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,685,358 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series E Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F1 · derivative.exercise_date: The Series E Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F1 · derivative.expiration_date: The Series E Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F2 · ownership.direct: These shares are are held directly by the Reporting Person. Longitude Capital Partners IV, LLC ("LCP4") is the general partner of the Reporting Person and may be deemed to have voting, investment and dispositive power over the shares held by the Reporting Person. Juliet Tammenoms Bakker, a member of the Issuer's board of directors, and Patrick G. Enright are managing members of LCP4 (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to the shares held by the Reporting Person. Each of LCP4 and the Managers disclaims beneficial ownership of the shares held by the Reporting Person and this report shall not be deemed an admission that any of them is the beneficial owner of such shares for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein..

Read SEC document
October 20, 2020 Filed Oct 23, 2020 00:24 UTC Eargo, Inc. EAR · Entity 94112 PurchaseCommon Stock 233,333 $18.00 $4,199,994.00
Disclosure

SEC source: 0000899243-20-029109 · doc4.xml · nonDerivative · entry 2

Longitude Venture Partners IV, L.P. · CIK 0001787456 · 10% owner

ENRIGHT PATRICK G · CIK 0001253886 · 10% owner

Longitude Capital Partners IV, LLC · CIK 0001829169 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,918,691

F2 · ownership.direct: These shares are are held directly by the Reporting Person. Longitude Capital Partners IV, LLC ("LCP4") is the general partner of the Reporting Person and may be deemed to have voting, investment and dispositive power over the shares held by the Reporting Person. Juliet Tammenoms Bakker, a member of the Issuer's board of directors, and Patrick G. Enright are managing members of LCP4 (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to the shares held by the Reporting Person. Each of LCP4 and the Managers disclaims beneficial ownership of the shares held by the Reporting Person and this report shall not be deemed an admission that any of them is the beneficial owner of such shares for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein..

Read SEC document
October 20, 2020 Filed Oct 23, 2020 00:24 UTC Eargo, Inc. EAR · Entity 94112 ConversionCommon Stock 3,685,358 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-029109 · doc4.xml · nonDerivative · entry 1

Longitude Venture Partners IV, L.P. · CIK 0001787456 · 10% owner

ENRIGHT PATRICK G · CIK 0001253886 · 10% owner

Longitude Capital Partners IV, LLC · CIK 0001829169 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,685,358

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series E Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F2 · ownership.direct: These shares are are held directly by the Reporting Person. Longitude Capital Partners IV, LLC ("LCP4") is the general partner of the Reporting Person and may be deemed to have voting, investment and dispositive power over the shares held by the Reporting Person. Juliet Tammenoms Bakker, a member of the Issuer's board of directors, and Patrick G. Enright are managing members of LCP4 (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to the shares held by the Reporting Person. Each of LCP4 and the Managers disclaims beneficial ownership of the shares held by the Reporting Person and this report shall not be deemed an admission that any of them is the beneficial owner of such shares for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein..

Read SEC document
October 13, 2020 Filed Oct 14, 2020 20:15 UTC Aimmune Therapeutics, Inc. AIMT · Entity 145931 Disposition to issuerStock Option (right to buy) · Derivative 15,398 $17.39 Strike: $17.11 $267,771.22
Disclosure

SEC source: 0000899243-20-028173 · doc4.xml · derivative · entry 10

ENRIGHT PATRICK G · CIK 0001253886 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,398 shares

Expires not disclosed

F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.

F4 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.

Read SEC document
October 13, 2020 Filed Oct 14, 2020 20:15 UTC Aimmune Therapeutics, Inc. AIMT · Entity 145931 Disposition to issuerStock Option (right to buy) · Derivative 11,432 $14.60 Strike: $19.90 $166,907.20
Disclosure

SEC source: 0000899243-20-028173 · doc4.xml · derivative · entry 9

ENRIGHT PATRICK G · CIK 0001253886 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,432 shares

Expires not disclosed

F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.

F4 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.

Read SEC document
October 13, 2020 Filed Oct 14, 2020 20:15 UTC Aimmune Therapeutics, Inc. AIMT · Entity 145931 Disposition to issuerStock Option (right to buy) · Derivative 7,500 $1.71 Strike: $32.79 $12,825.00
Disclosure

SEC source: 0000899243-20-028173 · doc4.xml · derivative · entry 8

ENRIGHT PATRICK G · CIK 0001253886 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,500 shares

Expires not disclosed

F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.

F4 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.

Read SEC document
October 13, 2020 Filed Oct 14, 2020 20:15 UTC Aimmune Therapeutics, Inc. AIMT · Entity 145931 Disposition to issuerStock Option (right to buy) · Derivative 17,500 $16.24 Strike: $18.26 $284,200.00
Disclosure

SEC source: 0000899243-20-028173 · doc4.xml · derivative · entry 7

ENRIGHT PATRICK G · CIK 0001253886 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,500 shares

Expires not disclosed

F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.

F4 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.

Read SEC document
October 13, 2020 Filed Oct 14, 2020 20:15 UTC Aimmune Therapeutics, Inc. AIMT · Entity 145931 Disposition to issuerStock Option (right to buy) · Derivative 19,755 $19.10 Strike: $15.40 $377,320.50
Disclosure

SEC source: 0000899243-20-028173 · doc4.xml · derivative · entry 6

ENRIGHT PATRICK G · CIK 0001253886 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 19,755 shares

Expires not disclosed

F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.

F4 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.

Read SEC document
October 13, 2020 Filed Oct 14, 2020 20:15 UTC Aimmune Therapeutics, Inc. AIMT · Entity 145931 Disposition to issuerStock Option (right to buy) · Derivative 52,421 $28.21 Strike: $6.29 $1,478,796.41
Disclosure

SEC source: 0000899243-20-028173 · doc4.xml · derivative · entry 5

ENRIGHT PATRICK G · CIK 0001253886 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 52,421 shares

Expires not disclosed

F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.

F4 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.

Read SEC document
October 13, 2020 Filed Oct 14, 2020 20:15 UTC Aimmune Therapeutics, Inc. AIMT · Entity 145931 Disposition to issuerStock Option (right to buy) · Derivative 65,849 $34.36 Strike: $0.14 $2,262,571.64
Disclosure

SEC source: 0000899243-20-028173 · doc4.xml · derivative · entry 4

ENRIGHT PATRICK G · CIK 0001253886 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 65,849 shares

Expires not disclosed

F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.

F4 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.

Read SEC document
October 13, 2020 Filed Oct 14, 2020 20:15 UTC Aimmune Therapeutics, Inc. AIMT · Entity 145931 Disposition to issuerCommon Stock, $0.0001 par value 7,840 $34.50 $270,480.00
Disclosure

SEC source: 0000899243-20-028173 · doc4.xml · nonDerivative · entry 3

ENRIGHT PATRICK G · CIK 0001253886 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F2 · shares: Disposed of to SPN MergerSub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated August 29, 2020, by and between the Issuer, Societes des Produits Nestle S.A., ("Nestle"), and Merger Sub (the "Merger Agreement"), commenced a tender offer to acquire any and all of the outstanding shares of the Issuer's common stock (other than those shares owned by Nestle and its affiliates) at a purchase price of $34.50 per share (the "Offer Price").

F3 · shares: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") vested in full, terminated, and was converted into the right to receive a cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of common stock subject to the RSU.

Read SEC document
October 10, 2020 Filed Oct 14, 2020 20:15 UTC Aimmune Therapeutics, Inc. AIMT · Entity 145931 OtherCommon Stock, $0.0001 par value 91,697 $34.50 $3,163,546.50
Disclosure

SEC source: 0000899243-20-028173 · doc4.xml · nonDerivative · entry 2

ENRIGHT PATRICK G · CIK 0001253886 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By: LCP2

Disclosed balance after: 0

F1 · ownership.nature: Reflects shares held by Longitude Capital Partners II, LLC ("LCP2"). The Reporting Person is a managing member of LCP2 and in his capacity as such may be deemed to share voting and investment power over the shares held by LCP2. The Reporting Person disclaims beneficial ownership over these securities and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

Read SEC document
October 10, 2020 Filed Oct 14, 2020 20:15 UTC Aimmune Therapeutics, Inc. AIMT · Entity 145931 OtherCommon Stock, $0.0001 par value 70,561 $34.50 $2,434,354.50
Disclosure

SEC source: 0000899243-20-028173 · doc4.xml · nonDerivative · entry 1

ENRIGHT PATRICK G · CIK 0001253886 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Read SEC document
September 30, 2020 Filed Oct 2, 2020 15:05 UTC Aptinyx Inc. APTX · Entity 120922 GrantStock Option (Right to Buy) · Derivative 8,379 $2.16 Strike: $3.38 $18,123.78
Disclosure

SEC source: 0001415889-20-002398 · form4-10022020_031001.xml · derivative · entry 1

ENRIGHT PATRICK G · CIK 0001253886 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,379

Underlying: Common Stock · 8,379 shares

Expires 2030-09-29

F1 · shares: The option award was issued to the Reporting Person, who elected to take equity awards in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.

F2 · derivative.exercise_date: This option is fully vested at time of grant.

Read SEC document
September 21, 2020 Filed Sep 24, 2020 01:35 UTC Aimmune Therapeutics, Inc. AIMT · Entity 145931 OtherCommon Stock, $0.0001 par value 91,697 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-026210 · doc4.xml · nonDerivative · entry 2

ENRIGHT PATRICK G · CIK 0001253886 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By: LCP2

Disclosed balance after: 91,697

F3 · kind: Represents a change in the form of ownership of LCP2 by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by LVP2.

F4 · ownership.nature: Reflects shares held by LCP2. The Reporting Person is a managing member of LCP2 and in his capacity as such may be deemed to share voting and investment power over the shares held by LCP2. The Reporting Person disclaims beneficial ownership over these securities and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

Read SEC document
September 21, 2020 Filed Sep 24, 2020 01:35 UTC Aimmune Therapeutics, Inc. AIMT · Entity 145931 OtherCommon Stock, $0.0001 par value 6,113,134 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-026210 · doc4.xml · nonDerivative · entry 1

ENRIGHT PATRICK G · CIK 0001253886 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By: LVP2

Disclosed balance after: 0

F1 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners II, L.P. ("LVP2") to its general and limited partners.

F2 · ownership.nature: Reflects shares that were held by LVP2. Longitude Capital Partners II, LLC ("LCP2") is the general partner of LVP2 and may be deemed to share voting and investment power over the shares of the Issuer held by LVP2. The Reporting Person is a managing member of LCP2 and in his capacity as such may be deemed to share voting and investment power over the shares held by LVP2. Each of LCP2 and the Reporting Person disclaim beneficial ownership over these securities and this report shall not be deemed an admission that either of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Read SEC document
August 28, 2020 Filed Sep 1, 2020 19:33 UTC Molecular Templates, Inc. MTEM · Entity 85987 SaleCommon Stock 1,049 $10.75 $11,272.66
Disclosure

SEC source: 0000899243-20-023790 · doc4.xml · nonDerivative · entry 2

Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner

Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner

ENRIGHT PATRICK G · CIK 0001253886 · 10% owner

Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.63 to $10.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

F3 · ownership.nature: These shares were held by a trust. Ms. Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Ms. Bakker, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 28, 2020 Filed Sep 1, 2020 19:33 UTC Molecular Templates, Inc. MTEM · Entity 85987 SaleCommon Stock 2,447 $10.75 $26,295.71
Disclosure

SEC source: 0000899243-20-023790 · doc4.xml · nonDerivative · entry 1

Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner

Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner

ENRIGHT PATRICK G · CIK 0001253886 · 10% owner

Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.63 to $10.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

F2 · ownership.nature: These shares were held directly by Juliet Tammenoms Bakker ("Ms. Bakker").

Read SEC document
August 06, 2020 Filed Aug 10, 2020 20:42 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 GrantNon-Qualified Stock Option (right to buy) · Derivative 6,765 $0.00 Strike: $127.07 $0.00
Disclosure

SEC source: 0001765581-20-000069 · edgardoc.xml · derivative · entry 2

ENRIGHT PATRICK G · CIK 0001253886 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,765

Underlying: Ordinary Shares · 6,765 shares

Expires 2030-08-05

F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in full on July 30, 2021.

Read SEC document
August 06, 2020 Filed Aug 10, 2020 20:42 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 GrantOrdinary Shares 2,705 $0.00 $0.00
Disclosure

SEC source: 0001765581-20-000069 · edgardoc.xml · nonDerivative · entry 1

ENRIGHT PATRICK G · CIK 0001253886 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,368

F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 30, 2021.

Read SEC document
July 28, 2020 Filed Jul 28, 2020 18:20 UTC Inozyme Pharma, Inc. INZY · Entity 77717 ConversionSeries A-2 Convertible Preferred Stock · Derivative 1,398,600 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-020572 · doc4.xml · derivative · entry 5

Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner

Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner

Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner

ENRIGHT PATRICK G · CIK 0001253886 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Longitude Venture Partners III, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 187,154 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F3 · derivative.exercise_date: On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F3 · derivative.expiration_date: On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2 · ownership.nature: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and dispositive power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and dispositive power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Read SEC document
July 28, 2020 Filed Jul 28, 2020 18:20 UTC Inozyme Pharma, Inc. INZY · Entity 77717 ConversionSeries A Convertible Preferred Stock · Derivative 15,000,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-020572 · doc4.xml · derivative · entry 4

Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner

Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner

Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner

ENRIGHT PATRICK G · CIK 0001253886 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Longitude Venture Partners III, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 2,007,225 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On July 28, 2020, the Series A Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F1 · derivative.exercise_date: On July 28, 2020, the Series A Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F1 · derivative.expiration_date: On July 28, 2020, the Series A Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2 · ownership.nature: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and dispositive power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and dispositive power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Read SEC document
July 28, 2020 Filed Jul 28, 2020 18:20 UTC Inozyme Pharma, Inc. INZY · Entity 77717 PurchaseCommon Stock 625,000 $16.00 $10,000,000.00
Disclosure

SEC source: 0000899243-20-020572 · doc4.xml · nonDerivative · entry 3

Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner

Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner

Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner

ENRIGHT PATRICK G · CIK 0001253886 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Longitude Venture Partners III, L.P.

Disclosed balance after: 2,819,379

F2 · ownership.nature: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and dispositive power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and dispositive power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Read SEC document
July 28, 2020 Filed Jul 28, 2020 18:20 UTC Inozyme Pharma, Inc. INZY · Entity 77717 ConversionCommon Stock 187,154 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-020572 · doc4.xml · nonDerivative · entry 2

Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner

Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner

Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner

ENRIGHT PATRICK G · CIK 0001253886 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Longitude Venture Partners III, L.P.

Disclosed balance after: 2,194,379

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2 · ownership.nature: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and dispositive power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and dispositive power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Read SEC document
July 28, 2020 Filed Jul 28, 2020 18:20 UTC Inozyme Pharma, Inc. INZY · Entity 77717 ConversionCommon Stock 2,007,225 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-020572 · doc4.xml · nonDerivative · entry 1

Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner

Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner

Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner

ENRIGHT PATRICK G · CIK 0001253886 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Longitude Venture Partners III, L.P.

Disclosed balance after: 2,007,225

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On July 28, 2020, the Series A Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2 · ownership.nature: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and dispositive power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and dispositive power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Read SEC document
July 10, 2020 Filed Jul 14, 2020 20:11 UTC 89bio, Inc. ETNB · Entity 73682 PurchaseCommon Stock 109,090 $27.50 $2,999,975.00
Disclosure

SEC source: 0000899243-20-019123 · doc4.xml · nonDerivative · entry 1

Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner

Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner

Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner

ENRIGHT PATRICK G · CIK 0001253886 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,600,877

F1 · shares: On July 10, 2020, Longitude Venture Partners III, L.P. ("Longitude Venture III") purchased 109,090 shares of the Issuer's common stock at a price of $27.50 per share in the Issuer's follow-on public offering.

F2 · ownership.nature: These shares are held directly by Longitude Venture III. Longitude Capital Partners III, LLC ("Longitude Capital III") is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of Longitude Capital III (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of Longitude Capital III and the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Read SEC document
June 30, 2020 Filed Jul 2, 2020 16:06 UTC Aptinyx Inc. APTX · Entity 120922 GrantStock Option (Right to Buy) · Derivative 5,436 $2.68 Strike: $4.17 $14,552.17
Disclosure

SEC source: 0001415889-20-001795 · form4-07022020_040733.xml · derivative · entry 1

ENRIGHT PATRICK G · CIK 0001253886 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,436

Underlying: Common Stock · 5,436 shares

Expires 2030-06-29

F1 · shares: The option award was issued to the Reporting Person, who elected to take equity awards in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.

F2 · derivative.exercise_date: This option is fully vested at time of grant.

Read SEC document
May 27, 2020 Filed May 29, 2020 23:13 UTC Aimmune Therapeutics, Inc. AIMT · Entity 145931 GrantStock Option (right to buy) · Derivative 15,398 $0.00 Strike: $17.11 $0.00
Disclosure

SEC source: 0000899243-20-014612 · doc4.xml · derivative · entry 3

ENRIGHT PATRICK G · CIK 0001253886 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,398

Underlying: Common Stock · 15,398 shares

Expires 2030-05-26

F3 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

Read SEC document
May 27, 2020 Filed May 29, 2020 23:13 UTC Aimmune Therapeutics, Inc. AIMT · Entity 145931 SaleCommon Stock, $0.0001 par value 7,840 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-014612 · doc4.xml · nonDerivative · entry 1

ENRIGHT PATRICK G · CIK 0001253886 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,401

F1 · shares: These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

Read SEC document
May 26, 2020 Filed May 28, 2020 21:07 UTC Molecular Templates, Inc. MTEM · Entity 85987 OtherCommon Stock 1,049 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-014482 · doc4.xml · nonDerivative · entry 4

Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner

Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner

ENRIGHT PATRICK G · CIK 0001253886 · 10% owner

Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,049

F3 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Capital III to its members.

F6 · ownership.nature: These shares are held by a trust. Ms. Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Ms. Bakker, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

Read SEC document
May 26, 2020 Filed May 28, 2020 21:07 UTC Molecular Templates, Inc. MTEM · Entity 85987 OtherCommon Stock 2,447 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-014482 · doc4.xml · nonDerivative · entry 3

Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner

Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner

ENRIGHT PATRICK G · CIK 0001253886 · 10% owner

Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,447

F3 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Capital III to its members.

F5 · ownership.nature: These shares are held directly by Ms. Bakker.

Read SEC document
May 26, 2020 Filed May 28, 2020 21:07 UTC Molecular Templates, Inc. MTEM · Entity 85987 OtherCommon Stock 3,495 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-014482 · doc4.xml · nonDerivative · entry 2

Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner

Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner

ENRIGHT PATRICK G · CIK 0001253886 · 10% owner

Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,495

F3 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Capital III to its members.

F4 · ownership.nature: These shares are held by a limited partnership (the "Partnership") of which the general partner is a trust (the "Trust"). Mr. Enright is the Trustee of the Trust and may be deemed to share voting, investment and dispositive power over the shares held by the Partnership. Each of the Trust and Mr. Enright disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Enright, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

Read SEC document
May 26, 2020 Filed May 28, 2020 21:07 UTC Molecular Templates, Inc. MTEM · Entity 85987 OtherCommon Stock 1,000,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-014482 · doc4.xml · nonDerivative · entry 1

Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner

Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner

ENRIGHT PATRICK G · CIK 0001253886 · 10% owner

Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Longitude Venture Partners III, L.P.

Disclosed balance after: 3,199,035

F1 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners III, L.P. ("Longitude Venture III") to its general and limited partners.

F2 · ownership.nature: These shares are held by Longitude Venture III. This report is filed jointly by Longitude Capital Partners III, LLC ("Longitude Capital III"), Longitude Venture III, Patrick G. Enright ("Mr. Enright"), and Juliet Tammenoms Bakker ("Ms. Bakker"). Longitude Capital III is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power over the shares held by Longitude Venture III. Mr. Enright and Ms. Bakker are the managing members of Longitude Capital III and may be deemed to share voting, investment and dispositive power over the shares held by Longitude Venture III. Each of Longitude Capital III, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein.

Read SEC document
May 20, 2020 Filed May 22, 2020 16:10 UTC Aptinyx Inc. APTX · Entity 120922 GrantStock Option (Right to Buy) · Derivative 40,000 $0.00 Strike: $3.84 $0.00
Disclosure

SEC source: 0001104659-20-065359 · a4.xml · derivative · entry 1

ENRIGHT PATRICK G · CIK 0001253886 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2030-05-19

F1 · derivative.exercise_date: This option vests in ratable monthly installments over one year from the date of grant.

Read SEC document
March 31, 2020 Filed Apr 2, 2020 16:26 UTC Aptinyx Inc. APTX · Entity 120922 GrantStock Option (Right to Buy) · Derivative 8,573 $1.36 Strike: $2.16 $11,624.99
Disclosure

SEC source: 0001567619-20-007434 · doc1.xml · derivative · entry 1

ENRIGHT PATRICK G · CIK 0001253886 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,573

Underlying: Common Stock · 8,573 shares

Expires 2030-03-30

F1 · shares: The option award was issued to the Reporting Person, who elected to take equity awards in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.

F2 · derivative.exercise_date: This option is fully vested at time of grant.

Read SEC document
March 18, 2020 Filed Mar 19, 2020 21:03 UTC Aimmune Therapeutics, Inc. AIMT · Entity 145931 PurchaseCommon Stock, $0.0001 par value 16,213 $11.06 $179,344.96
Disclosure

SEC source: 0000899243-20-009016 · doc4.xml · nonDerivative · entry 3

ENRIGHT PATRICK G · CIK 0001253886 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,561

F3 · price: The price reported in Column 4 is a weighted price. These Shares were purchased in multiple transactions at prices ranging from $10.66 to $11.50 inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares purchased at each separate price within the range set forth in this footnote.

Read SEC document
March 17, 2020 Filed Mar 19, 2020 21:03 UTC Aimmune Therapeutics, Inc. AIMT · Entity 145931 PurchaseCommon Stock, $0.0001 par value 8,787 $11.50 $101,050.50
Disclosure

SEC source: 0000899243-20-009016 · doc4.xml · nonDerivative · entry 2

ENRIGHT PATRICK G · CIK 0001253886 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,348

Read SEC document
March 17, 2020 Filed Mar 19, 2020 21:03 UTC Aimmune Therapeutics, Inc. AIMT · Entity 145931 PurchaseCommon Stock, $0.0001 par value 100,000 $11.40 $1,139,650.00
Disclosure

SEC source: 0000899243-20-009016 · doc4.xml · nonDerivative · entry 1

ENRIGHT PATRICK G · CIK 0001253886 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By: LVP2

Disclosed balance after: 6,113,134

F1 · price: The price reported in Column 4 is a weighted price. These Shares were purchased in multiple transactions at prices ranging from $11.35 to $11.50 inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares purchased at each separate price within the range set forth in this footnote.

F2 · ownership.nature: Longitude Capital Partners II, LLC ("LCP II") is the general partner of Longitude Venture Partners II, L.P. ("LVP II") and may be deemed to have voting, investment and dispositive power with respect to such securities. The Reporting Person (a member of the Issuer's board of directors) and Juliet Tammenoms Bakker are the managing members of LCP II. Each of LCP II, Ms. Tammenoms Bakker and the Reporting Person disclaim beneficial ownership over such securities except to the extent of their respective pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.